Hib Was Supposed to Be Gone. It Isn't.

Hook

In the 1980s, Haemophilus influenzae type b killed or permanently disabled thousands of children every year in the United States alone.

Then the vaccine arrived. Coverage climbed. Cases fell by more than 95%.

By the mid-1990s, Hib had largely dropped out of public consciousness. Paediatricians who trained after that point have rarely — if ever — seen a case. It felt solved.

It isn’t.

Context

CDC Morbidity and Mortality Weekly Report (MMWR) data have continued to surface Hib cases in circumstances that highlight a persistent and uncomfortable pattern: vaccination success does not mean uniform protection.

What the surveillance picture shows:

Cases cluster where vaccination coverage is incomplete — whether due to access barriers, hesitancy, or gaps in catch-up scheduling
Disparities are visible across demographic lines — Alaska Native communities, for example, have historically faced disproportionate Hib burden, a pattern that reflects broader structural inequities in healthcare access
Immunocompromised individuals remain at risk regardless of prior vaccination status or herd immunity levels
Infants too young to have completed the primary course remain a biologically vulnerable window — even in high-coverage settings

None of this is new in principle. But each surveillance cycle that surfaces avoidable Hib cases is a reminder that coverage statistics mask uneven distributions. A national average of 90% coverage means something very different from 90% coverage everywhere.

Your Take

The vaccine success paradox

Vaccination programs are, in a precise sense, victims of their own success.

When a disease becomes rare, the perceived risk of the disease drops. The perceived risk of the vaccine — which never disappears from public consciousness, even when it is minimal — does not fall at the same rate. The asymmetry creates drift.

Parents who have never seen a child with Hib meningitis make a different intuitive calculation than parents who have. This is not irrationality. It is the expected consequence of success. But it creates fragility.

Uneven coverage creates pockets, not protection

Herd immunity is not a uniform shield. It is a probabilistic aggregate that can fail locally even when the national number looks strong.

A community with 70% vaccination coverage — whether due to geography, hesitancy, access, or a cohort of missed infants — functions as a corridor for transmission. Hib can circulate and find its way to an unvaccinated infant or an immunocompromised adult with no exposure to the public health headline.

The gap between “nearly eliminated” and “eliminated” is not academic. It is where children still get meningitis.

Clinicians are less familiar than they used to be

There is a second-order risk that does not show up in vaccination statistics.

A generation of clinicians has trained in an environment where Hib disease is genuinely rare. The differential diagnosis patterns, the urgency reflexes, the instinct to consider invasive bacterial disease in a febrile child — these are skills that erode when they are rarely needed.

Rare diseases get diagnosed late. Epiglottitis can be fatal within hours of symptom onset. Bacterial meningitis causes permanent neurological damage in a window that is measured in hours, not days.

Familiarity matters. And it is thinning.

Implications

For parents: A child who has not completed the Hib vaccination schedule — including catch-up doses — carries meaningful risk that does not have to exist. This is fixable. Check your child’s immunisation record. If doses are missing, ask about catch-up.

A febrile child who seems unusually unwell — particularly with neck stiffness, difficulty swallowing, drooling, or stridor — needs urgent assessment. Do not wait.

For clinicians: Hib should remain on the differential for severe bacterial presentations in young unvaccinated or incompletely vaccinated children. The rarity of the disease makes it easy to not think of. That is exactly the condition under which delayed diagnosis happens.

For patients presenting with epiglottitis or acute bacterial meningitis, the question of vaccination status is clinically relevant — not just epidemiologically interesting.

For public health systems: Coverage data reported as national averages obscure pockets of vulnerability. Granular, local data on vaccination rates — particularly among infants completing primary courses — matter more than headline percentages.

Equity is not a footnote to vaccination policy. Communities with lower access to care are the communities where preventable cases accumulate. Surveillance without follow-through on access gaps is not a strategy.

FAQ

Is Hib still a real threat? Yes, in specific populations. Children who are unvaccinated or incompletely vaccinated, those with immune deficiencies, and communities with low coverage remain genuinely at risk. Rare does not mean zero.

Isn’t herd immunity supposed to prevent this? Herd immunity reduces transmission across a population, but it is not uniform. Local gaps in coverage create local vulnerabilities. It also does not protect immunocompromised individuals who cannot mount an adequate immune response even after vaccination.

What should I do if I’m not sure about my child’s vaccination history? Contact your GP, paediatrician, or immunisation provider. In Australia, the Australian Immunisation Register (AIR) holds vaccination records. Catch-up schedules exist and are effective — incomplete vaccination is correctable.

Why isn’t this getting more attention? Because the disease is rare in aggregate, and rare things are hard to sustain attention on. That is the paradox. The rarity is the result of the vaccine working. But rarity creates the conditions for complacency that allow the gaps to persist.

Closing

Hib was not defeated. It was suppressed by a technology that requires continuous, equitable, and attentive maintenance.

Stop maintaining it — unevenly, locally, quietly — and it comes back.

That is not a warning about the future. It is a description of what is already happening in the gaps.